Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12

scientific article published on 01 August 1999

Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12 is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID10463604

P50authorMichael T LotzeQ89121415
P2093author name stringRobbins PD
Tahara H
Nishioka Y
Hirao M
P433issue16
P921main subjectdendritic cellQ506253
P304page(s)4035-4041
P577publication date1999-08-01
P1433published inCancer ResearchQ326097
P1476titleInduction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
P478volume59

Reverse relations

cites work (P2860)
Q93133060A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Q42925679Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials
Q33820300CCL21 Cancer Immunotherapy
Q35939476Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains.
Q27349546Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation
Q35149637Classification of current anticancer immunotherapies
Q36325239Current immunotherapeutic strategies for central nervous system tumors
Q37448957Dendritic cell-based therapeutic cancer vaccines: what we have and what we need
Q34649397Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies.
Q41520681Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
Q37513871Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4
Q74445927Deregulated cytokine network and defective Th1 immune response in multiple myeloma
Q34672927Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells
Q36751608Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines
Q39509585IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
Q37665296Immunosuppressive effect of bladder cancer on function of dendritic cells involving of Jak2/STAT3 pathway
Q53574230Immunotherapeutic effects on murine pancreatic carcinoma by β-elemene combined with dendritic cells modified with genes encoding interleukin-23.
Q37144014Immunotherapy for liver tumors: present status and future prospects.
Q73924199Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer
Q35988030Intratumoral immunotherapy: using the tumour against itself
Q92661488Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
Q84925660OP9‐DL1 cell co‐culture enhances anti‐tumour immunity of mouse bone marrow‐derived dendritic cells
Q24793668Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells
Q35034010Past, present and future targets for immunotherapy in ovarian cancer
Q37735454Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors
Q48219588Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.
Q89509390Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome?
Q92441659Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill
Q92542097Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
Q35176307Targeting the tumor microenvironment to enhance antitumor immune responses
Q42093293Therapeutic response in patients with advanced malignancies treated with combined dendritic cell-activated T cell based immunotherapy and intensity-modulated radiotherapy
Q33711540Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant
Q53109846Trial watch: Dendritic cell-based anticancer immunotherapy
Q27024047Trial watch: Dendritic cell-based anticancer therapy
Q36388529Trial watch: Dendritic cell-based interventions for cancer therapy
Q42867339Trial watch: Dendritic cell-based interventions for cancer therapy
Q35174485Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN
Q58862665Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha
Q58780996Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Q36671200Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

Search more.